The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Open accessAbstract
Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The disease has been the subject of intensive research at both the basic scientific and clinical levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas. Although patients with EGFR-mutant tumours have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clinical problem. This Review summarizes recent developments aimed at treating and ultimately curing the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The third-generation drug retains the acrylamide group and covalently binds to Cys797, but replaces the quinazoline portion of the first- and second-generation compounds with pyrimidine to promote selectivity for T790M, showing a higher affinity for T790M than WT-EGFR.119”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [119]
In the citing paper
“Mutations in EGFR occur in 10-35% of NSCLCs and confer sensitivity to the EGFR TKIs erlotinib, gefitinib, and afatinib (6).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [6]
In the citing paper
“Exon 20 insertion mutations comprise 4–10% of all EGFR mutations 27,29–32.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [30]
In the citing paper
“Indeed, while ERBB2 gene amplifications and gain-of-function EGFR mutations support the proliferation of various cancer cell types (Oh and Bang, 2020; Pao and Chmielecki, 2010), VEGFA is critical for tumor-driven neoangiogenesis (Apte et al., 2019) and TGFb promotes the establishment of a fibrotic microenvironment that is poorly permissive to access by therapeutics (Derynck et al., 2020).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Pao and Chmielecki, 2010
In the citing paper
“Over the past two decades, a number of mAbs and TKIs have been developed to target these proteins or their binding partners, and some of these molecules, including HER2-, EGFR-, and VEGFA-specific agents, have been licensed for use in a variety of oncological indications (Apte et al., 2019; Oh and Bang, 2020; Pao and Chmielecki, 2010).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Pao and Chmielecki, 2010
In the citing paper
“EGFR mutations are primarily localized within two hot spots of the kinase domains, a series of overlapping deletions in exon 19 and a leucine to arginine substitution at amino acid position 858 (L858R) [reviewed in (Pao and Chmielecki, 2010)].”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Pao and Chmielecki, 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Approximately 2–3% of NSCLCs harbour mutations in BRAF , which encodes a signalling molecule downstream of EGF”
BackgroundJemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“Another 5% of tumours harbour translocations in anaplastic lymphoma kinase ( ALK”
Background
Flagged first, then by citations
Research works printed but not linked: 1
- Oh, I.-J. et al. in AACR–IASLC Joint Conference on Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy (Coronado, California USA, 2010).
Cited by
Sorted by citations
Items 801–900 of 1,000
Zhao, Y. (2019) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/332/3/032023 · Cited by 5
“Many studies([5,6]) have shown that NSCLC patients cancer cells are often observed with EGFR dysfunction.”
BackgroundXu, L., Ni, N., Gao, H., & Hu, P.-B. (2021) · Oncology Letters · doi:10.3892/ol.2021.12589 · Cited by 5
[Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].
Li, Y., Liu, H., & Chen, J. (2014) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2014.08.08 · Cited by 5
Liakakos, T., Katsios, C. G., & Roukos, D. H. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.1 · Cited by 5
Got a Light? Illuminating Lung Cancer
McAllister, S. S. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004446 · Cited by 5
“Tyrosine kinase inhibitors that target mutant EGFR have proven benef cial for a number of patients; however, EGFR inhibition is not as ef ective in patients whose tumors express wild-type EGFR, and many tumors develop resistance to EGFR inhibitors (5).”
BackgroundInfluentialFrom Traditional Molecular Biology to Network Oncology
Ziogas, D. E., Katsios, C. G., & Roukos, D. H. (2011) · Future Oncology · doi:10.2217/fon.10.190 · Cited by 5
Hu, X., Wang, D., Tong, Y., Tong, L., Wang, X., Zhu, L., Xie, H., Li, S., Yang, Y., & Xu, Y. F. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00101 · Cited by 5
“In contrast, thirdgeneration TKIs such as osimertinib, WZ4002, and CO-1686 bearing an anilinopyrimidine core, showed high potency and selectivity for EGFR L858R/T790M over WT EGFR, therefore serving as mutant-selective TKIs targeting EGFR mutants involved in NSCLC (Zhou et al., 2009; Walter et al., 2013; Cross et al.,…”
BackgroundInfluentialPeddapelli, S., Bandgar, M. D., Kapavarapu, R., Boruwa, J., Palabindela, R., & Narsimha, S. (2025) · ChemistrySelect · doi:10.1002/slct.202500049 · Cited by 4
Varlı, M., Zhou, R., Liu, R., Rho, J. K., Ha, H., Hur, J., & Kim, H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156973 · Cited by 5
Dutta, S., Rajesh, R., Matada, G. S. P., Paik, A., Dasgupta, A., Pal, R., Kushal, J., & Pavani, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118538 · Cited by 4
Acquired resistance of cancer therapies: Mechanisms and perspectives
Wang, M., Zhai, X., Li, J., Chen, J., Gai, X., Liu, X., Liu, Y., Zhou, Q., & Chen, C. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004048 · Cited by 5
“[243,244] The development of novel inhibitors and the application of combination strategies are important approaches to overcome EGFR TKI resistance.”
Ma, Y., Zhang, F., Li, J., Li, J., & Li, Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1436033 · Cited by 5
Lee, H.-Y., Hsieh, M., Liao, H., Chen, P., Chiang, X.-H., Tsou, K., Tsai, T.-M., Chuang, J.-H., Lin, M., Hsu, H., et al. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2021.747249 · Cited by 4
El cáncer de pulmón de células no pequeñas en la era de la medicina de precisión
Rivas, S., & Armisén, R. (2022) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2022.01.001 · Cited by 4
ASK120067 (limertinib) exerts pre-clinical anti-tumor activity by inhibiting EGFR exon20 insertion
Zhang, T., Fěng, F., Tong, L., Chan, S., Chen, Y., Li, Y., Song, P., Liu, Y., Bai, G., Lai, M., et al. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1050687 · Cited by 4
“Other 3rd-generation EGFR TKIs, almonertinib and al fl utinib also have been approved by the National Medical Products Administration (NMPA) of China for the second-line treatment T790M mutation-positive NSCLC patients (Pao and Chmielecki, 2010; Rosell et al., 2012; Cooper et al., 2022).”
Tang, C., Wang, J., Wang, D., Wang, H., Cui, S., Xiao, T., Fan, W., & Zhang, Y. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129648 · Cited by 4
A literature review of a meta-analysis of BRAF mutations in non-small cell lung cancer
Chimbangu, C. T., Li, X., Zhou, Y., Jiayue, Z., Xiao, M., Wang, Y., Xing-xu, Y., & Liu, X. (2024) · Medicine · doi:10.1097/md.0000000000034654 · Cited by 4
Anastasi, S., Alemà, S., & Segatto, O. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6528-7_14 · Cited by 4
Carpentier, O., Selvaggi, L., Jegu, J., Purohit, A., Prim, N., Velten, M., & Quoix, É. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.05.001 · Cited by 4
Mini Review: The Application of Omics in Targeted Anticancer Biopharmaceuticals Development
Zhou, L. (2014) · Cited by 4
The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative
Won, B. M., Carey, G. B., Tan, Y. C., Bokhary, U., Itkonen, M., Szeto, K., Wallace, J. A., Campbell, N. P., Hensing, T. A., & Salgia, R. (2016) · Cureus · doi:10.7759/cureus.533 · Cited by 4
Hong, J. H., Jung, S., Kim, M. S., Lee, S. H., & Chung, Y. (2017) · Pathology · doi:10.1016/j.pathol.2017.01.011 · Cited by 4
Ma, Y., Li, Q., Du, Y., Chen, W., Liu, X., Ye, L., Li, H., Wang, X., Liu, J., Shen, Z., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s255947 · Cited by 4
JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells
Pan, Z., Chen, Q., Zheng, X., Wang, K., Duan, Y., Xiao, K., Jia, Z., & Ding, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s254464 · Cited by 4
Peng, P., Yang, J., Colley, M. M. S., & Yang, T. (2021) · Photonics · doi:10.3390/photonics8120533 · Cited by 4
Paradigms for the development of transformative medicines—lessons from the EGFR story
Pao, W. J., & Nagel, Y. A. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.005 · Cited by 4
Self-citationGürsoy, P., Tatlı, A. M., Erdem, D., Göker, E., Çelik, E., Demirci, N. S., Sakin, A., Atçı, M. M., Bayram, E., Telli, T. A., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03984-5 · Cited by 4
Rúgolo, J. R. M., Baldavira, C. M., Prieto, T. G., Olivieri, E. H. R., Fabro, A. T., Rainho, C. A., Castelli, E. C., Ribolla, P. E. M., Ab’Saber, A. M., Takagaki, T. Y., et al. (2023) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2023e12488 · Cited by 4
“Uncommon EGFR mutations, such as the exon 20 insertion mutation, could result in primary resistance to EGFR target therapy (17).”
BackgroundDai, H., Jiao, Y., Sun, Z., Cao, Z., & Chen, X. (2018) · Biomedical Optics Express · doi:10.1364/boe.9.004149 · Cited by 4
Kim, E. Y., Lee, S. H., Kim, A., Kim, T., & Chang, Y. S. (2019) · Journal of Cancer · doi:10.7150/jca.32897 · Cited by 4
“The EGFR-TKI sensitizing mutations are defined as a point mutation in the EGFR exon 21, which substitutes an arginine for a leucine (L858R), in-frame deletions (encompassing 4 amino acid residues 747 to 750 LREA motif) of the EGFR exon 19, G719X point mutation(encoded by exon 18), and L861Q point mutation (exon 21)[17…”
BackgroundDugger, R. W., Li, B., & Richardson, P. (2019) · ACS symposium series · doi:10.1021/bk-2019-1332.ch002 · Cited by 4
Aye, P. S., McKeage, M. J., Tin, S. T., Khwaounjoo, P., & Elwood, M. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101847 · Cited by 4
Rihawi, K., Giampieri, R., Scartozzi, M., Pusceddu, V., Bonotto, M., Fasola, G., Cascinu, S., & Aprile, G. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1054479 · Cited by 4
“Similar to the T790M mutation of resistance to tyrosine kinase inhibitors in patients with NSCLC [75], a mutation in the extracellular domain of EGFR (namely S492R) has been shown to confer resistance to cetuximab, by preventing it from binding to EGFR, but not to panitumumab [73].”
BackgroundKristeleit, H., Enting, D., & Lai, R. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70186-1 · Cited by 4
Velcheti, V., Khunger, M., & Abazeed, M. E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.273 · Cited by 4
Zhu, W., Li, H., Fang, K., Zhang, B., Zhou, S., Zhang, Y., Le, H., & Hu, X.-F. (2018) · Disease Markers · doi:10.1155/2018/2942618 · Cited by 4
“EGFR mutations are the most common genetic lesions in adenocarcinoma but are very rare in squamous cell carcinoma [5].”
BackgroundLes inhibiteurs de tyrosine kinase
Robert, J. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1472 · Cited by 4
Crizotinib in ALK-positive lung cancer
Girard, N. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70375-3 · Cited by 4
Preface: Targeting the Human Kinome for Cancer Therapy
Daly, R. J. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.10 · Cited by 4
Liao, Z., Kempson, I. M., Fa, Y., Liu, M.-C., Hsieh, L.-C., Huang, K., & Wang, L. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00356 · Cited by 4
Non-nucleic acid biomarkers in early detection of lung cancer
Saravanan, S., Baskar, R., Devendiran, V., Palaniappan, N. A., Wahab, M. R. A., Manivannan, S., Rab, S. O., Saeed, M., & Palaniyandi, T. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120642 · Cited by 3
Tirpe, A., Nutu, A. M., Busuioc, C. I., Pop, O. L., & Berindan‐Neagoe, I. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1677471 · Cited by 5
“Two of the most frequent EGFR activating mutations are the L858R point mutation in exon 21 and the LREA in-frame deletion on exon 19 (19, 24).”
PINK1-Mediated Inhibition of EGFR Dimerization and Activation Impedes EGFR-Driven Lung Tumorigenesis
Lin, E. P.-Y., Huang, B., Lai, W., Tseng, Y., Yang, S., Kuo, H.-C., & Yang, P. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2582 · Cited by 3
“Activating mutations in the EGFR tyrosine kinase domain (EGFR-TKD) turn EGFR into a driver oncogene in lung cancer (1).”
BackgroundUysal, M., Beypınar, İ., & Araz, M. (2024) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1459_20 · Cited by 3
Rahman, M. A. (2024) · Nano LIFE · doi:10.1142/s1793984424500144 · Cited by 3
Chen, X.-P., He, S.-X., Chen, M., Chen, F., Wu, P., Shi, P., Zhao, S.-C., Zhao, L.-Y., Xiong, X.-M., & Zeng, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299447 · Cited by 5
Fifteen important questions for oncology to be addressed from 2015
Blay, J., Trédan, O., Ray-Coquard, I. L., Rivoire, M. L., Mehlen, P., Puisieux, A., & Bachelot, T. (2015) · Bulletin du Cancer · doi:10.1016/s0007-4551(15)31214-5 · Cited by 3
Jiang, T., & Zhou, C. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.02.03 · Cited by 3
Castellanos, E. H., Rivera, G. A., Wakelee, H. A., & Horn, L. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.02.005 · Cited by 3
Beth Levine’s Legacy: From the Discovery of BECN1 to Therapies. A Mentees’ Perspective
An, Z., Chiang, W., Fernández, Á. F., Franco, L. H., He, C., Huang, S., Lee, E., Liu, Y., Sebti, S., Shoji-Kawata, S., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.891332 · Cited by 4
“The downstream targets of EGFR, including PI3K, AKT, and mTOR, are well-recognized autophagy inhibitory molecules; therefore, autophagy is often induced in NSCLC during TKI therapy (Pao and Chmielecki, 2010).”
BackgroundParvar, S. Y., Rezvani, A., Ghaderpanah, R., Hefzosseheh, M., Rafiei, S., & Monabati, A. (2023) · Health Science Reports · doi:10.1002/hsr2.1369 · Cited by 3
Du, C., Qi, Z., & Zhang, W. J. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010259632240213091136 · Cited by 3
Ye, F., Yuan, X., Yu, W., Ma, Y., Mao, C., Li, X., Li, J., Dai, C., Qian, F.-H., Li, J., et al. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241273198 · Cited by 3
“35 However, long-term treatment with EGFR-TKIs often results in drug resistance, which remains an unavoidable dilemma for NSCLC patients.”
BackgroundTherapeutic Efficacy of Nanocarrier‐Mediated Inhalable Gene Transfection for Lung Cancer
Sarkar, P., Sardar, M., Sen, O., Das, S., & Manna, S. (2024) · ChemistrySelect · doi:10.1002/slct.202402903 · Cited by 4
Biomarkeranalytik aus Sicht des Pathologen
Buettner, R., & Heydt, C. (2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-013-1823-1 · Cited by 3
Chen, V. C., Iwama, E., Kim, I., & Giaccone, G. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.032 · Cited by 3
Zhang, S., Tian, H., Jiang, Q., Li, L., Ding, Y., Dai, L., Yu, X., Shen, G., Cheng, L., Huang, Q., et al. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.626480 · Cited by 3
Powers, A. D., Han, W., Bi, L., & Palecek, S. P. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-6963-5 · Cited by 3
“In some cases, this resistance is caused by an additional mutation in the EGFR kinase [35].”
BackgroundMethodInfluentialStella, G. M., Cemmi, F., Inghilleri, S., Zorzetto, M., Luisetti, M., & Pozzi, E. (2011) · Journal of Cancer · doi:10.7150/jca.2.474 · Cited by 3
Iommelli, F., Rosa, V. D., Fonti, R., & Vecchio, S. D. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0050-6 · Cited by 4
“Small insertions or duplications in exon 20 are associated with primary resistance to EGFR TKIs and occur in about 5 % of NSCLC cases [18].”
BackgroundPark, J. Y., Jang, S. H., Kim, H. J., Park, Y. B., Kwon, J. H., Song, H. H., Lee, K. W., Kim, J. H., Kim, J., Park, S. H., et al. (2011) · The Korean Journal of Internal Medicine · Cited by 3
EGFR inhibition generates drug-tolerant persister cells by blocking AKT activity
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1045 · Cited by 3
Shukla, S., Patel, A. S., & Ambudkar, S. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-23476-2_10 · Cited by 3
Development of taxane-containing chemotherapy of doxorubicin-resistant diffuse large B-cell lymphoma
Wu, L., Wang, J., Li, Y., Zuo, L., Zhang, Z., Ouyang, J., Fan, J., & Li, H. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000067 · Cited by 3
A High-Content Assay to Screen for Modulators of EGFR Function
Antczak, C., & Djaballah, H. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3073-9_8 · Cited by 3
Abnormal laboratory results: Tumour markers
Faulkner, D., & Meldrum, C. J. (2012) · Australian Prescriber · doi:10.18773/austprescr.2012.052 · Cited by 3
Mangla, A., Agarwal, N., Carmel, C., & Lad, T. E. (2016) · Rare Tumors · doi:10.4081/rt.2016.6410 · Cited by 3
Chae, Y. K., de Viveiros, P. A. H., Heleno, C. T., Bilal, H., Sukhadia, B., Oh, M. S., Sheikh, M. M., Iams, W. T., & Park, L. C. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00295 · Cited by 3
Zhang, L., Ren, H., Wu, Q., Wu, Y.-J., & Song, X. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00669-2 · Cited by 3
Duggirala, K. B., Choe, H., Jeon, B. U., Jung, M. E., Go, A., Lim, B., Park, C., Yoon, J., Chae, C. H., Cho, B. C., et al. (2019) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.11886 · Cited by 3
Tai, A., & Lin, S. (2022) · Statistics in Medicine · doi:10.1002/sim.9501 · Cited by 3
Common variable immunodeficiency in an adult with recurrent pneumonia.
Kart, L., Tor, M. M., Altın, R., Tekin, İ. Ö., Sayarlůoglu, H., Ustundag, Y., & Gun, B. D. (2003) · PubMed · Cited by 3
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasisPreprint
Gen, S., Tanaka, I., Morise, M., Koyama, J., Kodama, Y., Matsui, A., Miyazawa, A., Hase, T., Hibino, Y., Yokoyama, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1433523/v1 · Cited by 3
Design, synthesis, and biological evaluation of novel aminopyrimidine derivatives as EGFR inhibitors
Wang, H., Gui, Y., Cui, S., Long, X., Fan, W., & Tang, C. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130188 · Cited by 2
Xie, Z., Zhou, Z., Chen, S., Li, Y., He, X., & Chen, G. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02259-z · Cited by 2
“Previous research shows that EGFR phosphorylation plays a role in downstream signaling transduction, which affects the proliferation and survival of tumor cells and serves as a diagnostic criterion for LAUD under certain conditions [2, 43].”
Truong, D. T., Ho, K., Thai, C. T., Dung, D. T. M., Nguyen, M. T., Phung, T. V. B., & Nguyen, M. T. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp00817d · Cited by 2
The role of RAB GTPases in predicting prognosis and therapy response in pancreatic cancer
Wang, J., Ma, J., Lei, S., Zhai, Y. R., Liao, Y., Hu, C., & Li, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-03209-4 · Cited by 2
“These drugs could have different off-target effects or might differentially affect downstream signaling pathways beyond EGFR [44].”
Nano‐Electro‐Sampling and Intelligent Analysis System for Real‐Time Gene Profiling of Living Cells
Huang, Z., Liu, F., Zhi, D., Liu, B., Tong, Y., Lv, C., Chen, X., Yan, S., Wu, C., Mu, W., et al. (2025) · Small · doi:10.1002/smll.202506688 · Cited by 2
Patient‐oriented Research in the Era of Personalized Medicine
Brown, N. J. (2012) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00394.x · Cited by 2
Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens
Yamanaka, S., Suzuki, S., Ito, H., Karnan, S., Hanamura, I., Okubo, I., Yoshikawa, K., Ono, S., Takahara, T., Satou, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021722 · Cited by 2
“However, MEC cells are not completely eliminated; instead, some cells survive [15,29].”
BackgroundPeng, L., Deng, H., Li, D., Li, W., & Wang, Y. (2023) · Updates in Surgery · doi:10.1007/s13304-023-01467-x · Cited by 2
“Currently, with progress in diagnostic approaches and cancer treatments, cancer survivors may live long enough [20].”
BackgroundMokgautsi, N., Wu, A. T. H., Cheng, S., Lee, J., George, T. A., & Chen, J.-H. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105561 · Cited by 2
Mutlu, D. (2025) · Cumhuriyet Science Journal · doi:10.17776/csj.1592097 · Cited by 2
Chevula, J., Balabadra, S., Munnaluri, R., & Manga, V. (2025) · Journal of Chemical Sciences · doi:10.1007/s12039-025-02362-1 · Cited by 2
Rong, T., Ai, C., Yang, T., Wu, Q., & Zhang, M. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03385-y · Cited by 2
“EGFR mutations and overexpression are considered important mechanisms in NSCLC occurrence and development and are pivotal targets for cancer treat-ment in clinical practice [24].”
Murase, Y., Koba, H., Kimura, H., Matsumoto, I., Ueda, T., Nomura, S., Arai, S., Terada, N., Yifeng, L., Nanjo, S., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108818 · Cited by 2
Using Integrated Cancer-on-Chip Platforms to Emulate and Probe Various Cancer Models
Tong, Z., Tong, W. Y., Peng, B., Wei, Y., Oddo, A., & Voelcker, N. H. (2019) · Springer eBooks · doi:10.1007/978-3-662-59596-1_4 · Cited by 3
Leng, X., Mei, J., & Liu, L. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.11.10 · Cited by 2
EGFR inhibition and more: a new generation growing up.
Enting, D., & Spicer, J. F. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.10.04 · Cited by 2
Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy
Lee, S. Y., & Park, J. Y. (2011) · Journal of Lung Cancer · doi:10.6058/jlc.2011.10.1.1 · Cited by 2
Twenty‐One Novel EGFR Kinase Domain variants in Patients with Nonsmall Cell Lung Cancer
Hasenahuer, M. A., Parisi, G. D., Gautier, M., Lazarowski, A., Bramuglia, G. F., & Fornasari, M. S. (2015) · Annals of Human Genetics · doi:10.1111/ahg.12127 · Cited by 2
“Most of these disease associated sequence variants are found in exons 18–21 (Pao & Chmielecki, 2010) of the EGFR gene and the most frequent, occurring in approximately 90% of cases are ∗Corresponding author: MARIA SILVINA FORNASARI, Departamento de Ciencia y Tecnologı́a, Universidad Nacional de…”
BackgroundBiomarkers for EGFR-Antagonist Response: In the Genes and on the Genes!
Easwaran, H., & Baylin, S. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0157 · Cited by 2
“Radiation and chemotherapy have been the first-line choice of treatment for patients with NSCLC, yielding a median survival duration of 7 to 8 months (3).”
BackgroundInfluentialChen, B., Luo, J., Gu, W., Shen, L., Wang, H., & Zhou, S. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0289-6 · Cited by 2
Hu, P., Han, D., Ruan, R., Zheng, L.-M., Chou, S.-H., & Tzeng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.7140 · Cited by 2
“Inhibition of the kinase domain of EGFR and the resultant oncogenic cell signaling disruption by small molecule inhibitors have been shown to be particularly beneficial in patients carrying the so-called “sensitizing mutations” such as L858R and the exon-19 deletion [1, 2], which contribute to nearly 90% of lung-cance…”
BackgroundStructure-Based Virtual Screening for Defeating Drug Resistant Form of EGFR Protein
Sharifi, A., Bagherzadeh, K., Golestanian, S., & Amanlou, M. (2016) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207319666160115132121 · Cited by 2
The 5000% case: a glimpse into the financial issue of lung cancer treatment
Remón, J., Bonastre, J., & Besse, B. (2016) · European Respiratory Journal · doi:10.1183/13993003.00548-2016 · Cited by 2
Guide to Targeted Therapies: EGFR mutations in NSCLC
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3 · Cited by 3
Medicinal Chemistry Case History: Osimertinib (AZD9291)
Ward, R. A., & Finlay, M. R. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12448-5 · Cited by 2
Tyrosine kinase inhibitors: What after complete remission of lung cancer?
Jazieh, A. R., Abdelhafiez, N., Olayan, A. A., Bamefleh, H., & Loutfi, S. I. (2017) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2017.02.003 · Cited by 2
Resistance of Colorectal Tumors to Anti-EGFR Antibodies
Trusolino, L., & Leto, S. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_1 · Cited by 2
Metadata
- Authors
- Pao, W., & Chmielecki, J.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Pao, William
- Venue
- Nature Reviews Cancer
- Published
- 2010-10-22
- Volume
- 10
- Issue
- 11
- Pages
- 760-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3072803
- OpenAlex
- W2090029719
- Cited by
- 1,083
- References
- 180
- Citations by year
- 2026: 24 · 2025: 43 · 2024: 54 · 2023: 49 · 2022: 45 · 2021: 65 · 2020: 79 · 2019: 56 · 2018: 69 · 2017: 72 · 2016: 90 · 2015: 82 · 2014: 93 · 2013: 93 · 2012: 104
- FWCI
- 14.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Vanderbilt University
- National Institutes of Health
- University of California, San Francisco
- National Cancer Institute (P30 CA 68485, R01CA121210, P01CA129243, CA90949, U54CA143798, P50CA090949, P30CA068485)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR-mutant non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitors, gefitinib, erlotinib, acquired drug resistance, primary resistance, targeted therapy
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Protein-Tyrosine Kinases, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
